Radiolabeled compounds targeting the prostate-specific membrane antigen
US11504441B2 · kind B2 · utility
0Cited by
9References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 9, 2021 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Jul 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D257/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.